Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Active not recruiting 23Recruiting 16Completed 12Unknown 4Terminated 4Not yet recruiting 2Withdrawn 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4Renal Insufficiency 2Paraproteinemias 2Neoplasms, Plasma Cell 2Neoplasms by Histologic Type 2Neoplasms 2Hematologic Diseases 2Blood Protein Disorders 2Monoclonal Gammopathy of Undetermined Significance 1Immunoglobulin Light-chain Amyloidosis 1Cryoglobulinemia, Familial Mixed 1Amyloidosis 1

Interventions

Dexamethasone 63Cyclophosphamide 39Bortezomib 36Melphalan 22Lenalidomide 22Thalidomide 17pomalidomide 16fludarabine 12daratumumab 10carfilzomib 10Doxorubicin 8Filgrastim 7Busulfan 6Prednisone 5Peripheral Blood Stem Cell Transplantation 5Bendamustine Hydrochloride 5selinexor 4sargramostim 4isatuximab 4fludarabine phosphate 4Surveys and Questionnaires 4Etoposide 4Clarithromycin 4Calcium Dobesilate 4liposomal doxorubicin 3ixazomib 3Radiotherapy 3Neoadjuvant Therapy 3Mycophenolic Acid 3Methylprednisolone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Multiple Myeloma × isatuximab × Clear all
NCT04287855 2023-01-10

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Poitiers University Hospital

Phase 2 Unknown
82 enrolled
Plasma cell

Multiple Myeloma

NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Hellenic Society of Hematology

Phase 2 Unknown
51 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT05114109 2021-11-09

ICE

Assistance Publique - Hôpitaux de Paris

Phase 2 Unknown
21 enrolled
Plasma cell

Cryoglobulinemia, Familial Mixed, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡